|  
Home
Provigil Information
A Solution for Sleepiness
Taking Provigil
Off-Label Provigil
Use
Journal Articles
Related Resources
Provigil in the News
About Provigil Web
|
 |
 |
 |

Expert Opin Emerg Drugs. 2004 Nov;9(2):293-302.
New drugs for the treatment of attention-deficit/hyperactivity disorder
Pataki CS, Feinberg DT, McGough JJ.
UCLA Neuropsychiatric Institute, Room 27-370C, 760 Westwood Plaza, Los
Angeles, CA 90024
Attention-deficit/hyperactivity disorder (ADHD) is the most common neuropsychiatric
disorder of childhood. Recent research indicates that ADHD most often
persists into adolescence and adulthood, and is associated with impairments
in academic, social and occupational functioning.
The ADHD diagnosis is based on history and clinical examination. There
are no objective laboratory measures for diagnosis. ADHD is largely heritable.
Its underlying pathophysiology has been theorised to include dysregulation
of inhibitory noradrenergic frontocortical activity on dopaminergic striatal
structures. Evidence shows that ADHD is highly responsive to pharmacological
treatments resulting in global functional improvements.
Although pharmacotherapy is recognised as the most effective treatment,
additional components to optimise ADHD management include proper educational
placement, parent management training and social skills development. Central
nervous system stimulants, specifically methylphenidate and amphetamine,
remain first-line pharmacological treatments. Atomoxetine, a selective
noradrenergic re-uptake inhibitor, is the first non-stimulant compound
to receive FDA approval for paediatric and adult ADHD. Other medication
classes, including alpha-agonist antihypertensives, tricyclic antidepressants,
other antidepressants such as buproprion, and the wake-promoting agent
modafinil, are prescribed in off-label therapy. Ongoing
development of new ADHD medications is expected to emphasise alternative
and extended-release delivery systems and non-stimulant compounds.
|
|